Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer: A drug-resistant duo.

Literature DB >> 22170679

Cancer: A drug-resistant duo.

Hugo Lavoie, Marc Therrien.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 22170679 DOI： 10.1038/480329a

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

15 in total

Review 1. Mechanistic principles of RAF kinase signaling.

Authors: Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal: Cell Mol Life Sci Date: 2010-09-06 Impact factor: 9.261

Review 2. The RAF proteins take centre stage.

Authors: Claudia Wellbrock; Maria Karasarides; Richard Marais
Journal: Nat Rev Mol Cell Biol Date: 2004-11 Impact factor: 94.444

3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors: Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal: N Engl J Med Date: 2005-02-24 Impact factor: 91.245

4. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

5. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Authors: Nikhil Wagle; Caroline Emery; Michael F Berger; Matthew J Davis; Allison Sawyer; Panisa Pochanard; Sarah M Kehoe; Cory M Johannessen; Laura E Macconaill; William C Hahn; Matthew Meyerson; Levi A Garraway
Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544

6. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors: Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal: Nature Date: 2010-02-03 Impact factor: 49.962

7. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors: Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal: Nature Date: 2010-09-30 Impact factor: 49.962

8. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors: Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal: Nature Date: 2010-03-18 Impact factor: 49.962

9. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors: Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

10. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).

Authors: Poulikos I Poulikakos; Yogindra Persaud; Manickam Janakiraman; Xiangju Kong; Charles Ng; Gatien Moriceau; Hubing Shi; Mohammad Atefi; Bjoern Titz; May Tal Gabay; Maayan Salton; Kimberly B Dahlman; Madhavi Tadi; Jennifer A Wargo; Keith T Flaherty; Mark C Kelley; Tom Misteli; Paul B Chapman; Jeffrey A Sosman; Thomas G Graeber; Antoni Ribas; Roger S Lo; Neal Rosen; David B Solit
Journal: Nature Date: 2011-11-23 Impact factor: 49.962

6 in total

1. The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation?

Authors: Chung-Jung Tsai; Ruth Nussinov
Journal: Phys Chem Chem Phys Date: 2014-01-21 Impact factor: 3.676

2. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.

Authors: Michael Röring; Ricarda Herr; Gina J Fiala; Katharina Heilmann; Sandra Braun; Anja E Eisenhardt; Sebastian Halbach; David Capper; Andreas von Deimling; Wolfgang W Schamel; Darren N Saunders; Tilman Brummer
Journal: EMBO J Date: 2012-04-17 Impact factor: 11.598

6. Teaching Real Data Interpretation with Models (TRIM): Analysis of Student Dialogue in a Large-Enrollment Cell and Developmental Biology Course.

Authors: Patricia Zagallo; Shanice Meddleton; Molly S Bolger
Journal: CBE Life Sci Educ Date: 2016 Impact factor: 3.325